Report Detail
Global Myotonic Dystrophy Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
- RnM4619102 |
- 26 September, 2024 |
- Global |
- 104 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.
Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
According to our (Global Info Research) latest study, the global Myotonic Dystrophy Drug market size was valued at US$ 46.4 million in 2023 and is forecast to a readjusted size of USD 72.4 million by 2030 with a CAGR of 6.6% during review period.
The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.
This report is a detailed and comprehensive analysis for global Myotonic Dystrophy Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Distribution Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Myotonic Dystrophy Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD$/Unit), 2019-2030
Global Myotonic Dystrophy Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD$/Unit), 2019-2030
Global Myotonic Dystrophy Drug market size and forecasts, by Type and by Distribution Channel, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD$/Unit), 2019-2030
Global Myotonic Dystrophy Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Unit), and ASP (USD$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Myotonic Dystrophy Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Myotonic Dystrophy Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, Sun Pharma, Mallinckrodt, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Myotonic Dystrophy Drug market is split by Type and by Distribution Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Distribution Channel in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Sodium Channel Blocker
Tricyclic Antidepressant
Other
Market segment by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Other
Major players covered
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Myotonic Dystrophy Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Myotonic Dystrophy Drug, with price, sales quantity, revenue, and global market share of Myotonic Dystrophy Drug from 2019 to 2024.
Chapter 3, the Myotonic Dystrophy Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Myotonic Dystrophy Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Distribution Channel, with sales market share and growth rate by Type, by Distribution Channel, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Myotonic Dystrophy Drug market forecast, by regions, by Type, and by Distribution Channel, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Myotonic Dystrophy Drug.
Chapter 14 and 15, to describe Myotonic Dystrophy Drug sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Myotonic Dystrophy Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Sodium Channel Blocker
- 1.3.3 Tricyclic Antidepressant
- 1.3.4 Other
- 1.4 Market Analysis by Distribution Channel
- 1.4.1 Overview: Global Myotonic Dystrophy Drug Consumption Value by Distribution Channel: 2019 Versus 2023 Versus 2030
- 1.4.2 Hospital Pharmacy
- 1.4.3 Retail Pharmacy
- 1.4.4 Other
- 1.5 Global Myotonic Dystrophy Drug Market Size & Forecast
- 1.5.1 Global Myotonic Dystrophy Drug Consumption Value (2019 & 2023 & 2030)
- 1.5.2 Global Myotonic Dystrophy Drug Sales Quantity (2019-2030)
- 1.5.3 Global Myotonic Dystrophy Drug Average Price (2019-2030)
2 Manufacturers Profiles
- 2.1 Lupin
- 2.1.1 Lupin Details
- 2.1.2 Lupin Major Business
- 2.1.3 Lupin Myotonic Dystrophy Drug Product and Services
- 2.1.4 Lupin Myotonic Dystrophy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Lupin Recent Developments/Updates
- 2.2 Teva
- 2.2.1 Teva Details
- 2.2.2 Teva Major Business
- 2.2.3 Teva Myotonic Dystrophy Drug Product and Services
- 2.2.4 Teva Myotonic Dystrophy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Teva Recent Developments/Updates
- 2.3 ANI Pharmaceuticals
- 2.3.1 ANI Pharmaceuticals Details
- 2.3.2 ANI Pharmaceuticals Major Business
- 2.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Product and Services
- 2.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 ANI Pharmaceuticals Recent Developments/Updates
- 2.4 Mylan
- 2.4.1 Mylan Details
- 2.4.2 Mylan Major Business
- 2.4.3 Mylan Myotonic Dystrophy Drug Product and Services
- 2.4.4 Mylan Myotonic Dystrophy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Mylan Recent Developments/Updates
- 2.5 Novartis
- 2.5.1 Novartis Details
- 2.5.2 Novartis Major Business
- 2.5.3 Novartis Myotonic Dystrophy Drug Product and Services
- 2.5.4 Novartis Myotonic Dystrophy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Novartis Recent Developments/Updates
- 2.6 Sun Pharma
- 2.6.1 Sun Pharma Details
- 2.6.2 Sun Pharma Major Business
- 2.6.3 Sun Pharma Myotonic Dystrophy Drug Product and Services
- 2.6.4 Sun Pharma Myotonic Dystrophy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Sun Pharma Recent Developments/Updates
- 2.7 Mallinckrodt
- 2.7.1 Mallinckrodt Details
- 2.7.2 Mallinckrodt Major Business
- 2.7.3 Mallinckrodt Myotonic Dystrophy Drug Product and Services
- 2.7.4 Mallinckrodt Myotonic Dystrophy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Mallinckrodt Recent Developments/Updates
3 Competitive Environment: Myotonic Dystrophy Drug by Manufacturer
- 3.1 Global Myotonic Dystrophy Drug Sales Quantity by Manufacturer (2019-2024)
- 3.2 Global Myotonic Dystrophy Drug Revenue by Manufacturer (2019-2024)
- 3.3 Global Myotonic Dystrophy Drug Average Price by Manufacturer (2019-2024)
- 3.4 Market Share Analysis (2023)
- 3.4.1 Producer Shipments of Myotonic Dystrophy Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
- 3.4.2 Top 3 Myotonic Dystrophy Drug Manufacturer Market Share in 2023
- 3.4.3 Top 6 Myotonic Dystrophy Drug Manufacturer Market Share in 2023
- 3.5 Myotonic Dystrophy Drug Market: Overall Company Footprint Analysis
- 3.5.1 Myotonic Dystrophy Drug Market: Region Footprint
- 3.5.2 Myotonic Dystrophy Drug Market: Company Product Type Footprint
- 3.5.3 Myotonic Dystrophy Drug Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Myotonic Dystrophy Drug Market Size by Region
- 4.1.1 Global Myotonic Dystrophy Drug Sales Quantity by Region (2019-2030)
- 4.1.2 Global Myotonic Dystrophy Drug Consumption Value by Region (2019-2030)
- 4.1.3 Global Myotonic Dystrophy Drug Average Price by Region (2019-2030)
- 4.2 North America Myotonic Dystrophy Drug Consumption Value (2019-2030)
- 4.3 Europe Myotonic Dystrophy Drug Consumption Value (2019-2030)
- 4.4 Asia-Pacific Myotonic Dystrophy Drug Consumption Value (2019-2030)
- 4.5 South America Myotonic Dystrophy Drug Consumption Value (2019-2030)
- 4.6 Middle East & Africa Myotonic Dystrophy Drug Consumption Value (2019-2030)
5 Market Segment by Type
- 5.1 Global Myotonic Dystrophy Drug Sales Quantity by Type (2019-2030)
- 5.2 Global Myotonic Dystrophy Drug Consumption Value by Type (2019-2030)
- 5.3 Global Myotonic Dystrophy Drug Average Price by Type (2019-2030)
6 Market Segment by Distribution Channel
- 6.1 Global Myotonic Dystrophy Drug Sales Quantity by Distribution Channel (2019-2030)
- 6.2 Global Myotonic Dystrophy Drug Consumption Value by Distribution Channel (2019-2030)
- 6.3 Global Myotonic Dystrophy Drug Average Price by Distribution Channel (2019-2030)
7 North America
- 7.1 North America Myotonic Dystrophy Drug Sales Quantity by Type (2019-2030)
- 7.2 North America Myotonic Dystrophy Drug Sales Quantity by Distribution Channel (2019-2030)
- 7.3 North America Myotonic Dystrophy Drug Market Size by Country
- 7.3.1 North America Myotonic Dystrophy Drug Sales Quantity by Country (2019-2030)
- 7.3.2 North America Myotonic Dystrophy Drug Consumption Value by Country (2019-2030)
- 7.3.3 United States Market Size and Forecast (2019-2030)
- 7.3.4 Canada Market Size and Forecast (2019-2030)
- 7.3.5 Mexico Market Size and Forecast (2019-2030)
8 Europe
- 8.1 Europe Myotonic Dystrophy Drug Sales Quantity by Type (2019-2030)
- 8.2 Europe Myotonic Dystrophy Drug Sales Quantity by Distribution Channel (2019-2030)
- 8.3 Europe Myotonic Dystrophy Drug Market Size by Country
- 8.3.1 Europe Myotonic Dystrophy Drug Sales Quantity by Country (2019-2030)
- 8.3.2 Europe Myotonic Dystrophy Drug Consumption Value by Country (2019-2030)
- 8.3.3 Germany Market Size and Forecast (2019-2030)
- 8.3.4 France Market Size and Forecast (2019-2030)
- 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
- 8.3.6 Russia Market Size and Forecast (2019-2030)
- 8.3.7 Italy Market Size and Forecast (2019-2030)
9 Asia-Pacific
- 9.1 Asia-Pacific Myotonic Dystrophy Drug Sales Quantity by Type (2019-2030)
- 9.2 Asia-Pacific Myotonic Dystrophy Drug Sales Quantity by Distribution Channel (2019-2030)
- 9.3 Asia-Pacific Myotonic Dystrophy Drug Market Size by Region
- 9.3.1 Asia-Pacific Myotonic Dystrophy Drug Sales Quantity by Region (2019-2030)
- 9.3.2 Asia-Pacific Myotonic Dystrophy Drug Consumption Value by Region (2019-2030)
- 9.3.3 China Market Size and Forecast (2019-2030)
- 9.3.4 Japan Market Size and Forecast (2019-2030)
- 9.3.5 South Korea Market Size and Forecast (2019-2030)
- 9.3.6 India Market Size and Forecast (2019-2030)
- 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
- 9.3.8 Australia Market Size and Forecast (2019-2030)
10 South America
- 10.1 South America Myotonic Dystrophy Drug Sales Quantity by Type (2019-2030)
- 10.2 South America Myotonic Dystrophy Drug Sales Quantity by Distribution Channel (2019-2030)
- 10.3 South America Myotonic Dystrophy Drug Market Size by Country
- 10.3.1 South America Myotonic Dystrophy Drug Sales Quantity by Country (2019-2030)
- 10.3.2 South America Myotonic Dystrophy Drug Consumption Value by Country (2019-2030)
- 10.3.3 Brazil Market Size and Forecast (2019-2030)
- 10.3.4 Argentina Market Size and Forecast (2019-2030)
11 Middle East & Africa
- 11.1 Middle East & Africa Myotonic Dystrophy Drug Sales Quantity by Type (2019-2030)
- 11.2 Middle East & Africa Myotonic Dystrophy Drug Sales Quantity by Distribution Channel (2019-2030)
- 11.3 Middle East & Africa Myotonic Dystrophy Drug Market Size by Country
- 11.3.1 Middle East & Africa Myotonic Dystrophy Drug Sales Quantity by Country (2019-2030)
- 11.3.2 Middle East & Africa Myotonic Dystrophy Drug Consumption Value by Country (2019-2030)
- 11.3.3 Turkey Market Size and Forecast (2019-2030)
- 11.3.4 Egypt Market Size and Forecast (2019-2030)
- 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
- 11.3.6 South Africa Market Size and Forecast (2019-2030)
12 Market Dynamics
- 12.1 Myotonic Dystrophy Drug Market Drivers
- 12.2 Myotonic Dystrophy Drug Market Restraints
- 12.3 Myotonic Dystrophy Drug Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Myotonic Dystrophy Drug and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Myotonic Dystrophy Drug
- 13.3 Myotonic Dystrophy Drug Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Myotonic Dystrophy Drug Typical Distributors
- 14.3 Myotonic Dystrophy Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Myotonic Dystrophy Drug. Industry analysis & Market Report on Myotonic Dystrophy Drug is a syndicated market report, published as Global Myotonic Dystrophy Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Myotonic Dystrophy Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
